Revenue Breakdown
Composition ()
No data
Revenue Streams
Heron Therapeutics Inc (HRTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is CINVANTI, accounting for 62.7% of total sales, equivalent to $23.95M. Other significant revenue streams include ZYNRELEF and APONVIE. Understanding this composition is critical for investors evaluating how HRTX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Heron Therapeutics Inc maintains a gross margin of 68.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9.93%, while the net margin is -45.78%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HRTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HRTX competes directly with industry leaders such as NAUT and STTK. With a market capitalization of $244.94M, it holds a significant position in the sector. When comparing efficiency, HRTX's gross margin of 68.82% stands against NAUT's N/A and STTK's 100.00%. Such benchmarking helps identify whether Heron Therapeutics Inc is trading at a premium or discount relative to its financial performance.
